SG11202010790XA - Cd73 inhibitors - Google Patents
Cd73 inhibitorsInfo
- Publication number
- SG11202010790XA SG11202010790XA SG11202010790XA SG11202010790XA SG11202010790XA SG 11202010790X A SG11202010790X A SG 11202010790XA SG 11202010790X A SG11202010790X A SG 11202010790XA SG 11202010790X A SG11202010790X A SG 11202010790XA SG 11202010790X A SG11202010790X A SG 11202010790XA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- Prior art date
Links
- 229940127272 CD73 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664841P | 2018-04-30 | 2018-04-30 | |
| US201862737647P | 2018-09-27 | 2018-09-27 | |
| US201862757714P | 2018-11-08 | 2018-11-08 | |
| US201862777697P | 2018-12-10 | 2018-12-10 | |
| US201962810790P | 2019-02-26 | 2019-02-26 | |
| PCT/US2019/030068 WO2019213174A1 (en) | 2018-04-30 | 2019-04-30 | Cd73 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010790XA true SG11202010790XA (en) | 2020-11-27 |
Family
ID=68386646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010790XA SG11202010790XA (en) | 2018-04-30 | 2019-04-30 | Cd73 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11325938B2 (en) |
| EP (1) | EP3787635A4 (en) |
| JP (2) | JP7489323B2 (en) |
| KR (1) | KR20210018255A (en) |
| CN (1) | CN112423764A (en) |
| AU (1) | AU2019261976A1 (en) |
| BR (1) | BR112020022068A2 (en) |
| CA (1) | CA3098493A1 (en) |
| IL (1) | IL304348B2 (en) |
| MX (2) | MX2020011542A (en) |
| SG (1) | SG11202010790XA (en) |
| TW (1) | TW202014182A (en) |
| WO (1) | WO2019213174A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| JP7489323B2 (en) | 2018-04-30 | 2024-05-23 | オリック ファーマシューティカルズ，インク． | CD73 inhibitors |
| US20210253614A1 (en) * | 2018-05-31 | 2021-08-19 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
| JP7538047B2 (en) * | 2018-06-21 | 2024-08-21 | アンテンジーン セラピューティクス リミテッド | Ectonucleotidase inhibitors and methods of use thereof |
| KR20210145787A (en) | 2019-04-02 | 2021-12-02 | 알리고스 테라퓨틱스 인코포레이티드 | Compounds targeting PRMT5 |
| CN116854758A (en) * | 2019-10-30 | 2023-10-10 | 欧瑞克制药公司 | CD73 inhibitors |
| EP4353732A1 (en) | 2021-05-11 | 2024-04-17 | Xizang Haisco Pharmaceutical Co., Ltd. | Small molecular cd73 antagonist and use thereof |
| US20240140979A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| US20240140980A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| CN116217644B (en) * | 2023-04-24 | 2023-08-08 | 南京颐媛生物医学研究院有限公司 | Anti-coronavirus ribonucleoside compound, and preparation method and application thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477454A1 (en) * | 1990-09-28 | 1992-04-01 | Merrell Dow Pharmaceuticals Inc. | Novel phosphonate derivatives of certain nucleosides |
| CA2429352A1 (en) | 2000-12-15 | 2002-06-20 | Lieven Stuyver | Antiviral agents for treatment of flaviviridae infections |
| US20040229839A1 (en) * | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US20090274686A1 (en) * | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
| US10654884B2 (en) | 2014-04-25 | 2020-05-19 | Boehringer Ingelheim International Gmbh | Purine derivatives as CD73 inhibitors for the treatment of cancer |
| CN104530166B (en) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | The method of selective reduction 4,6-conjugated diene-3-ketosteroid compound |
| WO2017098421A1 (en) * | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| EP3399984B1 (en) | 2016-01-08 | 2023-09-06 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| CN110234656B (en) * | 2016-09-09 | 2023-02-28 | 卡利泰拉生物科技公司 | Exonucleotidase inhibitors and methods of use thereof |
| WO2018067424A1 (en) * | 2016-10-03 | 2018-04-12 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| EP3541396A4 (en) | 2016-11-18 | 2020-07-22 | Arcus Biosciences, Inc. | Inhibitors of cd73-mediated immunosuppression |
| US10570167B2 (en) | 2016-12-22 | 2020-02-25 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| JP2020515559A (en) * | 2017-03-31 | 2020-05-28 | ぺロトン セラピューティクス，インク． | CD73 inhibitors and their use |
| WO2018208727A1 (en) | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| JP7489323B2 (en) | 2018-04-30 | 2024-05-23 | オリック ファーマシューティカルズ，インク． | CD73 inhibitors |
| US20210253614A1 (en) | 2018-05-31 | 2021-08-19 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
| JP7538047B2 (en) | 2018-06-21 | 2024-08-21 | アンテンジーン セラピューティクス リミテッド | Ectonucleotidase inhibitors and methods of use thereof |
| EP3843714A4 (en) | 2018-08-27 | 2022-04-20 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| US20220363709A1 (en) | 2019-06-20 | 2022-11-17 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| WO2021011689A1 (en) | 2019-07-16 | 2021-01-21 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| CN116854758A (en) | 2019-10-30 | 2023-10-10 | 欧瑞克制药公司 | CD73 inhibitors |
-
2019
- 2019-04-30 JP JP2020560361A patent/JP7489323B2/en active Active
- 2019-04-30 MX MX2020011542A patent/MX2020011542A/en unknown
- 2019-04-30 TW TW108115143A patent/TW202014182A/en unknown
- 2019-04-30 BR BR112020022068-0A patent/BR112020022068A2/en unknown
- 2019-04-30 SG SG11202010790XA patent/SG11202010790XA/en unknown
- 2019-04-30 CN CN201980044455.4A patent/CN112423764A/en active Pending
- 2019-04-30 IL IL304348A patent/IL304348B2/en unknown
- 2019-04-30 AU AU2019261976A patent/AU2019261976A1/en active Pending
- 2019-04-30 KR KR1020207034512A patent/KR20210018255A/en not_active Application Discontinuation
- 2019-04-30 CA CA3098493A patent/CA3098493A1/en active Pending
- 2019-04-30 EP EP19796584.1A patent/EP3787635A4/en active Pending
- 2019-04-30 WO PCT/US2019/030068 patent/WO2019213174A1/en unknown
-
2020
- 2020-10-23 US US17/078,567 patent/US11325938B2/en active Active
- 2020-10-29 MX MX2023002507A patent/MX2023002507A/en unknown
-
2022
- 2022-03-17 US US17/697,318 patent/US11807658B2/en active Active
-
2023
- 2023-09-28 US US18/476,763 patent/US20240124512A1/en active Pending
-
2024
- 2024-05-13 JP JP2024078186A patent/JP2024112864A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019213174A1 (en) | 2019-11-07 |
| EP3787635A4 (en) | 2022-03-02 |
| JP7489323B2 (en) | 2024-05-23 |
| US20220220147A1 (en) | 2022-07-14 |
| EP3787635A1 (en) | 2021-03-10 |
| IL304348B1 (en) | 2024-04-01 |
| MX2020011542A (en) | 2020-11-24 |
| US20210047359A1 (en) | 2021-02-18 |
| US11807658B2 (en) | 2023-11-07 |
| TW202014182A (en) | 2020-04-16 |
| IL304348B2 (en) | 2024-08-01 |
| AU2019261976A1 (en) | 2020-12-03 |
| MX2023002507A (en) | 2023-03-13 |
| CA3098493A1 (en) | 2019-11-07 |
| JP2021522280A (en) | 2021-08-30 |
| IL304348A (en) | 2023-09-01 |
| CN112423764A (en) | 2021-02-26 |
| US20240124512A1 (en) | 2024-04-18 |
| BR112020022068A2 (en) | 2021-04-20 |
| KR20210018255A (en) | 2021-02-17 |
| JP2024112864A (en) | 2024-08-21 |
| US11325938B2 (en) | 2022-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277006A (en) | Cd73 inhibitors | |
| IL283639A (en) | Kif18a inhibitors | |
| IL304348A (en) | Cd73 inhibitors | |
| IL269196A (en) | Novel inhibitors | |
| EP3843714A4 (en) | Cd73 inhibitors | |
| GB201705971D0 (en) | Inhibitor compounds | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| SG11202110534QA (en) | Cd73 inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| EP3600301A4 (en) | Kdm4 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| GB2578396B (en) | Amidodiamine corrosion inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| EP3745112C0 (en) | Rotating-compensator ellipsometer | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201806130D0 (en) | Inhibitor compounds | |
| GB201806131D0 (en) | Inhibitor compounds | |
| GB201721465D0 (en) | Inhibitors |